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The structure and subcellular localization of a number of molecules change during
apoptosis. These molecules are recognized by the immune system, leading to the
development of autoimmunity when apoptotic cells fail to be effectively cleared by
phagocytosis. We searched for such molecules by analyzing sera from 12 individuals
who suffered from autoimmune diseases and from 3 patients with amyotrophic lat-
eral sclerosis. One serum sample, designated 681, detected an antigen that fulfilled
the above criteria. In Western blotting of lysates of human Jurkat T cells, the 681 anti-
gen appeared as a distinct signal with a molecular mass of 60 kDa in normal cells, and
2 additional signals with faster mobilities were detected in apoptotic cells. The
results of subcellular fractionation and immunofluorescence experiments revealed
this antigen to be strictly localized in the nucleus of normal cells, but to be translo-
cated to a region near the plasma membrane, to membrane blebs in particular, after
the induction of apoptosis. Under conditions in which membrane blebbing was inhib-
ited in apoptotic cells, the antigen still moved away from the nucleus, but its accumu-
lation at the periplasmic region was completely abolished. The apparent partial
cleavage and intracellular redistribution of the 681 antigen in apoptotic cells mimics
changes previously reported for the nuclear autoantigen La, but the 681 antigen was
clearly distinct from La. These results suggest that cleavage-dependent exit from the
nucleus during apoptosis is a phenomenon common to nuclear autoantigens.
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Phagocytic clearance of cells undergoing apoptosis plays
roles not only in preventing organisms from being
exposed to the noxious contents of dying cells but also in
more actively maintaining tissue homeostasis by directly
eliminating microbe-infected cells, producing anti-infla-
mmatory substances, and presenting antigens to T lym-
phocytes (Refs. 1–3 for reviews). Dysregulation of the
clearance of apoptotic cells could result in the develop-
ment of serious diseases such as acquired immunodefi-
ciency syndrome, neurodegenerative diseases, and auto-
immune diseases.
Autoimmune diseases are characterized by the pro-
duction of autoantibodies that induce inflammatory
responses in organisms. Most antigens recognized by
autoantibodies are molecules that exist within cells
under normal conditions. However, once cells are broken,
they are recognized by immune surveillance and evoke
autoimmunity. Many types of aged, spent, or non-self
cells routinely die in great numbers via apoptosis. These
cells are rapidly and selectively eliminated through apop-
tosis-dependent phagocytosis by both circulating and tis-
sue-restricted phagocytes. Apoptotic cells exhibit necrotic
characteristics sometimes called secondary necrosis
when they are left unremoved. Necrosis is a mode of cell
death in which the cellular contents leak out through
broken plasma membranes. It is therefore reasonably
anticipated that a failure of apoptotic cells to undergo
phagocytic clearance could lead to autoimmune diseases
(Ref. 4 for a review). In fact, a deficiency of phagocytosis
of apoptotic cells mediated by complement C1q (5–7) or
the tyrosine kinase c-mer (8, 9) results in the develop-
ment of autoimmunity. In addition, the injection of apop-
totic cells induces the production of autoantibodies in
mice (10, 11).
Both the structure and composition of the cell surface
change during apoptosis. The most obvious change is the
occurrence of membrane blebbing, in which parts of the
plasma membrane protrude, and cells eventually come to
look like raspberries (Ref. 12 for a review). As a less
dynamic change, the structures of surface sugar chains
are altered by the action of glycosidases that cleave off
terminal sugars during apoptosis (Ref. 13 for a review).
Another type of fine tuning observed in many types of
apoptotic cells is the redistribution of membrane phos-
pholipids; phospholipids confined to the inner leaflet of
the membrane bilayer in normal cells, such as phosphati-
dylserine and phosphatidylethanolamine, translocate to
the outer leaflet and are exposed on the cell surface (Ref.
14 for a review). These changes make apoptotic cells dis-
tinguishable from normal cells. Selective recognition andVol. 133, No. 2, 2003 211 © 2003 The Japanese Biochemical Society.
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the specific binding of phagocytosis markers, which exist
at the surface of apoptotic cells, to their receptors present
on phagocytes. Until now, various molecules have been
proposed as such phagocytosis markers and their recep-
tors (Refs. 2, 14, and 15 for reviews). In most cases, pre-
existing molecules acquire the function of phagocytosis
markers after cellular molecules are externalized or sur-
face molecules are structurally modified upon the induc-
tion of apoptosis. Those phagocytosis markers may at the
same time be recognized by the immune system as non-
self antigens. If the phagocytic clearance of apoptotic
cells is inhibited or delayed, phagocytosis markers
present at the surface of apoptotic cells might evoke
autoimmunity (16). In fact, some autoantigens move to a
region near the cell periphery during apoptosis (Ref. 4 for
a review): the nuclear autoantigen La translocates from
the nucleus to the cytoplasm or plasma membrane upon
infection with herpes simplex virus type 1 (17) or adeno-
virus 2 (18); fragmented endoplasmic reticulum, ribos-
omes, the ribonucleoprotein Ro, nucleosomal DNA, La,
and small nuclear ribonucleoproteins are relocalized to
plasma membrane blebs in UV-irradiated cells (19); Ro
and La become detectable at the surface of staurosporine-
treated cells (20, 21); La is cleaved and relocalized to the
cytoplasm in UV-irradiated cells (22); ribosomal proteins
S15, P0, L5, L6, L36a, and L41 are externalized at the
cell surface during doxorubicin-induced apoptosis (23). It
is therefore reasonably anticipated that the translocation
of cellular antigens to the plasma membrane plays a
causative role in autoimmunity.
In the present study, we analyzed sera of autoimmune
disease patients searching for molecules whose subcellu-
lar localizations change during apoptosis.
MATERIALS AND METHODS
Cell Culture and Apoptosis Analysis—Jurkat cells, a
human leukemia T-cell line, were grown in RPMI 1640
containing 10% fetal bovine serum at 37C in a humidi-
fied atmosphere of 5% CO2 in air. The cells were treated
with doxorubicin (Sigma, St. Louis, MO, USA) (0.3 g/ml)
or CH11, an agonistic anti-human Fas antibody (0.1 g/
ml) (MBL, Nagoya), for the induction of apoptosis as
described previously (24, 25). The occurrence of plasma
membrane blebbing was morphologically determined by
phase contrast microscopy. For inhibition of membrane
blebbing, cells were pre-treated with the ROCK-I inhibi-
tor Y-27632 (0.1 mM) (Mitsubishi Welpharma, Tokyo) 1 h
before the induction of apoptosis (26). To examine the
occurrence of chromatin condensation, cells were stained
with the DNA-binding fluorochrome Hoechst 33342 and
analyzed by florescence-phase contrast microscopy.
Human Sera—Serum samples were obtained with
informed consent from 17 donors: 12 patients suffering
from autoimmune diseases including myasthenia gravis
(6 patients), multiple sclerosis (1 patient), systemic lupus
erythematosis (1 patient), chronic inflammatory demyeli-
nating polyradiculoneuropathy (2 patients), acute inflam-
matory demyelinating polyradiculoneuropathy (1 patient),
and Sjögren’s syndrome (1 patient). In addition, serum
samples from 3 patients with amyotrophic lateral sclero-
sis and from 2 healthy individuals were obtained. Either
unfractionated serum or the IgG fraction prepared by
protein A–Sepharose chromatography was used in the
study. Another serum sample from a Sjögren’s syndrome
patient, which was positive for the Ro antigen and nega-
tive for the La antigen, was used to detect Ro in Western
blotting.
Preparation of Cell Lysates—To obtain whole-cell
lysates, Jurkat cells were lysed in buffer containing 62.5
mM Tris-HCl (pH 6.8), 2.5% (w/v) SDS, and 2.5% (v/v) 2-
mercaptoethanol, incubated on ice for 30 min, and centri-
fuged at 18,000 g for 15 min at 4C, and the superna-
tants were collected. For subcellular fractionation,
Jurkat cells were disrupted using a glass-Teflon homoge-
nizer in buffer consisting of 0.13 M KCl and 25 mM Tris-
HCl (pH 7.5), centrifuged at 900 g for 5 min at 4C, and
the supernatants and pellets (nuclear faction) were
collected. The supernatants were further centrifuged at
100,000 g for 60 min at 4C, and the supernatants
(cytosol fraction) and pellets (membrane fraction) were
collected. The membrane fraction was solubilized as for
the preparation of whole-cell lysates and analyzed by
Western blotting.
Western Blotting—Protein samples were separated by
12% (w/v) SDS–polyacrylamide gel electrophoresis and
transferred onto a polyvinylidene difluoride membrane
(Immobilon P; Millipore, Bedford, MA, USA). The mem-
brane was blocked with 5% (w/v) dry skim milk, reacted
first with primary IgG antibodies, and then with horse-
radish peroxidase–conjugated anti-human IgG (Immu-
notech, Marseilles, France) or alkaline phosphatase-con-
jugated anti-mouse IgG (Bio-Rad Laboratories, Hercules,
CA, USA), and subjected to a chemiluminescence reac-
tion with Renaissance substrates (NEN Life Science
Products, Boston, MA, USA) or Immun-Star substrates
(Bio-Rad Laboratories). The primary antibodies used in
this study were IgG preparations purified from human
serum samples and mouse anti-La monoclonal IgG (22).
Immunofluorescence and Flow Cytometry—For im-
munofluorescence analysis, cells were smeared on 3-
amino-propyltriethoxysilane–coated glass slides and in-
cubated with IgG from human serum samples or anti-La
monoclonal antibody. Cells incubated with human IgG
were treated with fluorescein isothiocyanate–labeled
anti-human IgG (Immunotech), and those incubated with
the anti-La antibody were successively treated with bioti-
nylated anti-mouse IgG antibody (Zymed, San Francisco,
CA, USA) and Alexa 488–labeled streptavidin (Molecular
Probe, Eugene, OR, USA). The samples were then exam-
ined under a fluorescence-phase contrast microscope or a
confocal laser-scanning microscope (LSM510; Carl Zeiss,
Jena, Germany). To locate autoantigens and DNA simul-
taneously, cells subjected to immunofluorescence were
further stained with Hoechst 33342, and examined by
fluorescence-phase contrast microscopy. For flow cytome-
try, cells were first incubated with IgG from human se-
rum or anti-La antibody, successively treated with fluo-
rescein isothiocyanate-labeled secondary antibodies, and
analyzed with a flow cytometer (Epics-XL; Coulter, Hi-
aleah, FL, USA).J. Biochem.
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Detection of Candidate Autoantigens—We first exam-
ined sera collected from 11 individuals suffering from
autoimmune diseases (8 patients) or amyotrophic lateral
sclerosis (3 patients) (see “MATERIALS AND METH-
ODS”) for the presence of antibodies that detected anti-
gens localized in the membrane fractions of apoptotic
cells. For this purpose, membrane-rich lysates prepared
from either normal or doxorubicin-treated Jurkat cells
were subjected to Western blotting with the 11 antibod-
ies. IgG fractions from healthy donors did not give signals
(data not shown), but most IgG fractions prepared from
the patients reacted with multiple proteins (Fig. 1A).
Many antibodies showed indistinguishable signal pat-
terns between lysates of normal and apoptotic cells. How-
ever, 2 antibodies, one (681) derived from a myasthenia
gravis patient and the other (111) from a patient with
chronic inflammatory demyelinating polyradiculoneu-
ropathy, gave signals specifically detectable with lysates
of apoptotic cells. These apoptotic cell–specific signals
Fig. 1. Detection of putative antigens cor-
responding to serum antibodies of auto-
immune disease patients. A: Membrane
fractions (50 g of protein) of Jurkat cells that
were treated (+) or not treated (–) with doxoru-
bicin for 24 h were analyzed by Western blot-
ting with IgG fractions prepared from sera of
11 patients (shown as arbitrary numbers at the
top of each panel). The positions of molecular
mass markers are shown on the left. Signals
that were detectable only with lysates of apop-
totic cells are indicated by arrowheads. B:
Whole-cell lysates (50 g of protein) and mem-
brane fractions (50 g of protein) were ana-
lyzed as above with 3 antibodies (681, 111, and
S-250). The positions and calculated molecular
masses of the 3 signals detected in lysates of
doxorubicin-treated cells with the 681 antibody
are indicated.
Fig. 2. Time course of changes of the 681 antigen. Whole-cell
lysates (50 g of protein) of Jurkat cells that had been treated (+) or
not treated (–) with CH11 for the indicated lengths of time were
analyzed by Western blotting with the 681 antibody. The positions
of molecular mass markers are shown on the left, and the positions
and molecular masses of the 3 signals detected in lysates of CH11-
treated cells are indicated on the right.Vol. 133, No. 2, 2003
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membrane fractions were compared (Fig. 1B). These
results indicate that these apoptosis-specific proteins are
associated with membranes. We decided to perform more
extensive analyses of the signals detected by the 681
antibody.
Apoptosis-Dependent Change of the 681 Antigen—We
next examined whether or not the above-described phe-
nomenon was restricted to a particular type of apoptosis
inducer. To test this, Jurkat cells were incubated with
CH11, an agonistic anti-Fas antibody, and whole-cell
lysates of these cells were analyzed by Western blotting
using the 681 antibody. The results clearly showed that
both 43- and 28-kDa signals became detectable in the
lysates of Jurkat cells upon treatment with CH11 (data
not shown, see Fig. 2). We next determined the time
course of the change in the 681 antigen during apoptosis.
Whole-cell lysates of Jurkat cells that had been treated
with CH11 for various lengths of time were analyzed by
Western blotting (Fig. 2). An increase in the intensity of
the 43- and 28-kDa signals became apparent as early as 2
h after the addition of the apoptosis inducer, at which
time Jurkat cells were positive for phosphatidylserine
externalization, chromatin condensation, and plasma
membrane blebbing (data not shown), and the signal
intensities continued to increase thereafter. The inten-
sity of the 60-kDa signal, in contrast, decreased as the
culture period was extended. These results indicate that
the change in the structure of the 681 antigen does not
depend on the apoptosis inducer and occurs at an early
stage of the apoptosis pathway. In addition, the 43- and
28-kDa proteins may be degradation products of the 60-
kDa protein.
Since 681 serum was derived from a myasthenia gravis
patient, we asked whether the 681 antigen is a common
antigen for this particular type of autoimmune disease.
To do so, whole-cell lysates of normal and apoptotic Jur-
kat cells were analyzed by Western blotting with sera of 4
more patients with the same disease. All the tested sera
gave the 60-kDa signal with normal cell lysates, although
its intensity was weak relative to that obtained with 681
serum and many other signals were also detectable (data
not shown). The presence of various signals made the
appearance of the apoptosis-specific 43- and 28-kDa sig-
nals in apoptotic Jurkat cells ambiguous (data not
shown). These results suggest that the 60-kDa protein is
a common antigen in myasthenia gravis, but no conclu-
sion was made as to the generality of its cleavage during
apoptosis.
Relocalization of the 681 Antigen during Apoptosis—
We next examined whether the subcellular localization of
the 681 antigen changes during apoptosis. Normal Jur-
Fig. 3. Localization of the 681
antigen in normal and apop-
totic cells. A: Jurkat cells that
had been treated or not treated
with CH11 for 2 h in the presence
or absence of Y-27632 were simul-
taneously analyzed by immun-
ofluorescence with the 681 anti-
body and staining with Hoechst
33342 for the localization of the
681 antigen and DNA (nuclei),
respectively. Views obtained by
fluorescence-phase contrast micro-
scopy are shown. B: Jurkat cells
that had been treated or not
treated with CH11 for 2 h in the
presence or absence of Y-27632
were analyzed by immunofluo-
rescence with the 681 antibody.
Views obtained by confocal laser
scanning microscopy are shown.
C: Jurkat cells that had been
treated or not treated with CH11
for 2 h in the presence or absence
of Y-27632 were simultaneously
analyzed by immunofluorescence
with anti-La antibody and stain-
ing with Hoechst 33342 for the
localization of the La antigen and
DNA (nuclei), respectively. Views
obtained by fluorescence-phase
contrast microscopy are shown. D:
Jurkat cells that had been
treated or not treated with CH11
for 2 h in the presence or absence
of Y-27632 were analyzed by
immunofluorescence with anti-
La antibody. Views obtained by
confocal laser scanning micros-
copy are shown. Bars = 10 m.J. Biochem.
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lized were subjected to immunofluorescence analysis
with the 681 antibody and examined by fluorescence
microscopy (Fig. 3A) or confocal laser scanning micros-
copy (Fig. 3B). The signal derived from the 681 antigen
was localized within the nucleus, which was identified by
staining cells with Hoechst 33342, a DNA-binding fluo-
rescent dye (top panels in Fig. 3A). Treatment with CH11
caused a relocalization of the 681 antigen: signals were
no longer detectable in the cell nucleus, and instead cell
bodies, in particular the region near plasma membrane
blebs, became positive in apoptotic Jurkat cells (bottom
panels but one in Fig. 3A and middle panels in Fig. 3B).
Not all membrane blebs in CH11-treated cells appeared
to contain the 681 antigen, and this could reflect a differ-
ential distribution of the antigen in small and large mem-
brane blebs as reported for other nuclear autoantigens (4,
19), although the physiological consequences of this phe-
nomenon remain to be determined. Similar results were
obtained with Jurkat cells undergoing doxorubicin-
induced apoptosis (data not shown). To examine the role
of membrane blebs in the redistribution of the 681 anti-
gen upon the induction of apoptosis, Jurkat cells were
induced to undergo apoptosis in the presence of the
ROCK-I inhibitor Y-27632 (27), which inhibits plasma
membrane blebbing. The presence of this drug com-
pletely abrogated membrane blebbing although the cells
underwent apoptosis, as indicated by nuclear fragmenta-
tion (bottom panels in Fig. 3, A and B), as previously
observed (26). In those cells, the 681 antigen did not
move to a position near the plasma membrane, but did
move away from the cell nucleus. Treatment with Y-
27632 did not affect the localization of the 681 antigen in
normal cells (second panels from the top in Fig. 3A).
These results indicate that the 681 antigen is a nuclear
protein whose localization moves to a place near plasma
membrane blebs upon the induction of apoptosis. The
accumulation of the antigen in the periplasmic region,
but not its exit from the cell nucleus, seems to be depend-
ent on the occurrence of membrane blebbing.
A similar change in subcellular localization during
apoptosis has been reported for another nuclear autoan-
tigen, La (17–22). To confirm this, we examined the local-
ization of La in normal and apoptotic Jurkat cells using a
monoclonal antibody specific for La (Fig. 3, C and D). The
results were similar to those obtained with the 681 anti-
body: signals were restricted to the cell nucleus in normal
cells, moved to a place near plasma membrane blebs
upon the induction of apoptosis, and stayed in the middle
of apoptotic cells in the presence of Y-27632. The 60-kDa
681 antigen is clearly distinct from known nuclear
autoantigens La and Ro as assessed by Western blotting
analyses using anti-La monoclonal antibody and human
serum positive for Ro (Fig. 4). This indicates that two dis-
tinct nuclear proteins, the 681 antigen and La, change
their intracellular distributions during apoptosis in a
similar manner. To correlate signals detected by immun-
ofluorescence with those detected by Western blotting,
Jurkat cells either treated or not treated with CH11 were
subjected to subcellular fractionation and analyzed by
Fig. 4. Distinction of the 681 antigen from La and Ro. Whole-
cell lysates (20 g of protein) of Jurkat cells that had been treated
(+) or not treated (–) with CH11 for 6 h were analyzed by Western
blotting with IgG of 681 serum, anti-La monoclonal IgG, or IgG of
Ro-positive serum. Arrowheads indicate signals derived from pre-
sumed intact antigens detectable with each antibody. The positions
of molecular mass markers are shown on the left.
Fig. 5. Detection of the 681 antigen in the subcellular frac-
tions of normal and apoptotic cells. Jurkat cells that had been
treated with CH11 for 6 h were subjected to subcellular fractiona-
tion. A: Each fraction together with whole-cell lysates (all equiva-
lent to 5  105 cells) were analyzed by Western blotting with 681
IgG. Fractions analyzed were whole-cell lysates (whole), nuclear
fraction (nucl), membrane fraction (memb), and cytosol fraction
(cyto). Arrowheads indicate the 681 antigen detected in each pro-
tein fraction. The positions of molecular mass markers are shown
on the left. B: The same protein fractions were separated in an
SDS–polyacrylamide gel and visualized by staining with Coomassie
Brilliant Blue. The positions of molecular mass markers are shown
on the left.Vol. 133, No. 2, 2003
216 A. Shiratsuchi et al.Western blotting with the 681 antibody (Fig. 5). In line
with the results of the immunofluorescence analyses, the
60-kDa protein was predominantly recovered in the
nuclear fraction prepared from normal Jurkat cells. Sig-
nificant portions of the 43- and 28-kDa proteins, which
were specifically detected in lysates of CH11-treated
cells, were present in the membrane fraction but not in
the cytosol fraction. In contrast, the 60-kDa signal was
restricted, at a reduced level, to the nuclear fraction pre-
pared from apoptotic cells. These results indicate that
signals detected by immunofluorescence outside the
nucleus in apoptotic Jurkat cells reflect the 43- and 28-
kDa proteins associated with membranes, and suggest
that the apoptosis-dependent exit of the 681 antigen from
the nucleus requires proteolytic cleavage.
Association of the 681 Autoantigen with Membrane
Blebs on the Cytoplasmic Side—We next used flow
cytometry to examine whether the 681 antigen is exposed
on the cell surface during apoptosis. The relevancy of the
flow cytometric detection of the 681 antigen was shown
Fig. 6. Absence of the 681 antigen on the surface of apoptotic
cells. A: Normal Jurkat cells were incubated on ice for 30 min with
phosphate-buffered saline containing 70% ethanol in order to perme-
abilize the plasma membranes. Cells with either intact or permeabi-
lized plasma membranes were analyzed for 681 or La antigen by flow
cytometry. Vertical lines indicate the position of a peak obtained with
control normal IgG. B, C: Jurkat cells that had been induced to
undergo apoptosis by treatment with CH11 for the indicated lengths
of time were analyzed by flow cytometry for the binding of 681 anti-
body (A) or anti-La antibody (B). Cells were simultaneously mixed
with antibodies and propidium iodide, and plasma membrane–per-
meabilized (top areas in panels of the left row) or –non-permeabi-
lized (bottom areas in panels of the left row) cells were gated and re-
plotted for the binding of antibodies (FITC). Numbers in panels of
the left row indicate percentage of cells in the corresponding areas.
Vertical lines in the panels of the right two rows indicate the position
of a peak obtained with control normal IgG.J. Biochem.
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stained only when the plasma membranes were permea-
bilized (Fig. 6A). Jurkat cells treated or not treated with
CH11 for varying lengths of time were incubated with
the 681 antibody and analyzed by flow cytometry. The
antibody did not bind to apoptotic Jurkat cells with non-
permeabilized plasma membranes while it efficiently
bound to cells positive for staining with propidium iodide
(Fig. 6B). Furthermore, the externalization of La during
apoptosis was not obviously detected under the condi-
tions adopted in this study (Fig. 6C). These results indi-
cate that the 681 antigen changes its structure and sub-
cellular localization during apoptosis, but is not
effectively externalized and exposed on the cell surface.
Results of subcellular fractionation experiments showed
that the 43- and 28-kDa proteins were mostly associated
with membranes in apoptotic cells (see Fig. 5). It is thus
likely that the 681 antigen undergoes proteolytic cleav-
age, exits the nucleus, and becomes associated with mem-
brane blebs on the cytoplasmic side after the induction of
apoptosis.
DISCUSSION
We searched for molecules whose structure and subcellu-
lar localization change during apoptosis by analyzing
sera obtained from 15 individuals including 12 patients
with autoimmune diseases. One serum sample, obtained
from a patient (anonymously designated 681) suffering
from myasthenia gravis, bound to an interesting 60-kDa
nuclear antigen that was distinct from the known
nuclear autoantigens, La and Ro. Serum samples from 4
more patients with the same disease detected this anti-
gen in Western blotting. An antibody recognizing the
nuclear La antigen plays roles in the development and
pathogenesis of systemic lupus erythematosis and Sjö-
gren’s syndrome. It can thus be speculated that an anti-
body to the 60-kDa nuclear antigen is involved in the
pathogenesis of myasthenia gravis, at least in some of its
subtypes, in addition to acetylcholine receptor-specific
autoantibodies (28).
Portions of the 60-kDa antigen appeared to be broken
down into 43- and 28-kDa proteins during apoptosis, and,
at the same time, the antigen translocated from the
nucleus to a position near plasma membrane blebs. The
accumulation of the antigen near the plasma membrane
was dependent on the occurrence of membrane blebbing,
and a fraction of the antigen seemed to be localized on the
cytoplasmic side of membrane blebs. The relocalization of
cytoplasmic or nuclear autoantigens during apoptosis
has been reported (4, 16). Furthermore, the nuclear
autoantigen La was recently shown to be transferred
from the nucleus to the cytoplasm in apoptotic cells after
its nuclear localization signal was cleaved off (22). The
newly discovered 681 antigen behaves in a similar man-
ner to the La antigen upon the induction of apoptosis.
However, it still remains to be clarified whether the 43-
and 28-kDa signals are degradation products of the 60-
kDa protein, and, if so, whether the redistribution of the
antigen requires its cleavage. In any case, cleavage-medi-
ated translocation to the cytoplasm might be a common
change in nuclear autoantigens during apoptosis. It will
be necessary to identify the 681 antigen and determine
the molecular basis for its structural alteration during
apoptosis in order to resolve the above issues.
Many autoantigens appear to accumulate in the vicin-
ity of plasma membrane blebs (4, 16). We show in the
present study that a putative nuclear autoantigen, desig-
nated 681, is localized near the plasma membrane in
apoptotic cells and that membrane blebbing is required
for this relocalization. The fact that membrane blebbing
as well as the redistribution of the 681 antigen were
inhibited by a ROCK-I inhibitor suggests that the redis-
tribution of the 681 antigen during apoptosis is mediated
by a signaling pathway involving this protein kinase.
Cocca et al. recently suggested that plasma membrane
blebbing causes autoantigens to become exposed on the
surface of apoptotic cells (29). However, our results indi-
cate that the 681 antigen remains on the cytoplasmic side
of membrane blebs in apoptotic Jurkat cells. Regardless
of cell surface exposure, it is important to determine the
functional significance of the subcellular relocalization of
nuclear autoantigens.
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